Peripheral nerve diseases

Pharmacological treatment for familial amyloid polyneuropathy

Abstract Background Disease‐modifying pharmacological agents for transthyretin (TTR)‐related familial amyloid polyneuropathy (FAP) have become available in the last decade, but evidence on their efficacy and safety is limited. This review focuses on disease‐modifying pharmacological treatment for TTR‐related and other FAPs, encompassing amyloid kinetic stabilisers, amyloid matrix solvents, and amyloid precursor inhibitors. Objectives To assess and […]

Share

Pharmacological treatment for familial amyloid polyneuropathy

Abstract Background Disease‐modifying pharmacological agents for transthyretin (TTR)‐related familial amyloid polyneuropathy (FAP) have become available in the last decade, but evidence on their efficacy and safety is limited. This review focuses on disease‐modifying pharmacological treatment for TTR‐related and other FAPs, encompassing amyloid kinetic stabilisers, amyloid matrix solvents, and amyloid precursor inhibitors. Objectives To assess and […]

Share

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome

Abstract Background Plasma exchange and intravenous immunoglobulin, but not corticosteroids, are beneficial in Guillain‐Barré syndrome (GBS). The efficacy of other pharmacological agents is unknown. This review was first published in 2011 and previously updated in 2013, and 2016. Objectives To assess the effects of pharmacological agents other than plasma exchange, intravenous immunoglobulin and corticosteroids for […]

Share

Interventions for ulceration and other skin changes caused by nerve damage in leprosy

Abstract Background At the end of 2016, 145 countries reported to the World Health Organization (WHO) over 173,000 new cases of leprosy worldwide. In the past 20 years, over 16 million people have been treated for leprosy globally. The condition’s main complications are injuries and ulceration caused by sensory loss from nerve damage. In this […]

Share

Interventions for ulceration and other skin changes caused by nerve damage in leprosy

Abstract available in English Español Français Background At the end of 2016, 145 countries reported to the World Health Organization (WHO) over 173,000 new cases of leprosy worldwide. In the past 20 years, over 16 million people have been treated for leprosy globally. The condition’s main complications are injuries and ulceration caused by sensory loss […]

Share

Genetic testing for prevention of severe drug‐induced skin rash

Abstract Background Drug‐induced skin reactions present with a range of clinical symptoms, from mild maculopapular skin rashes to potentially fatal blistering skin rashes — such as Stevens‐Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) — which may result in death. Milder reactions may be troublesome and lead to low drug compliance. The pathogenesis of these […]

Share

Interventions for treating neuropathic pain in people with sickle cell disease

Abstract Background Pain is the hallmark of sickle cell disease (SCD) and it can be severe, frequent and unpredictable. Although nociceptive pain is more common, at times, people with SCD may have neuropathic pain. The latter can occur due to peripheral or central nerve injury. This review is focused on identifying treatment of only painful […]

Share

Interventions for treating neuropathic pain in people with sickle cell disease

Abstract Background Pain is the hallmark of sickle cell disease (SCD) and it can be severe, frequent and unpredictable. Although nociceptive pain is more common, at times, people with SCD may have neuropathic pain. The latter can occur due to peripheral or central nerve injury. This review is focused on identifying treatment of only painful […]

Share

Acetyl‐L‐carnitine for the treatment of diabetic peripheral neuropathy

Abstract Plain language summary Acetyl‐L‐carnitine for the treatment of diabetic neuropathy The aim of this review The aim of this review was to assess the effects of acetyl‐L‐carnitine (ALC) on diabetic peripheral neuropathy (DPN) in people with diabetes. We were particularly interested in whether ALC could relieve pain, and also aimed to identify any harmful […]

Share

Herbal medicinal products or preparations for neuropathic pain

Abstract Neuropathic pain is a consequence of damage to the central nervous system (CNS), for example, cerebrovascular accident, multiple sclerosis or spinal cord injury, or peripheral nervous system (PNS), for example, painful diabetic neuropathy (PDN), postherpetic neuralgia (PHN), or surgery. Evidence suggests that people suffering from neuropathic pain are likely to seek alternative modes of […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share